Integration of CD4⁺ T cells and molecular subtype predicts benefit from PD-L1 blockade in muscle-invasive bladder cancer.

ABSTRACT: Muscle-invasive bladder cancer (MIBC) is a disease characterized by molecular and clinical heterogeneity, posing challenges in selecting the most appropriate treatment in clinical settings. Considering the significant role of CD4⁺ T cells, there is an emerging need to integrate CD4⁺ T cells with molecular subtypes to refine classification. We conducted a comprehensive study involving 895 MIBC patients from four independent cohorts. The Zhongshan Hospital (ZSHS) and The Cancer Genome Atlas (TCGA) cohorts were included to investigate chemotherapeutic response. The IMvigor210 cohort was included to assess the immunotherapeutic response. NCT03179943 was used to evaluate the clinical response to a combination of immune checkpoint blockade (ICB) and chemotherapy. Additional

SUBMITTER: Liu G 

PROVIDER: S-EPMC11007017 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature